TISIDB

Summary
Symbol	FZD8
Name	frizzled class receptor 8
Aliases	frizzled (Drosophila) homolog 8; frizzled homolog 8 (Drosophila); frizzled 8, seven transmembrane spanning r ......
Chromosomal Location	10p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane; Multi-pass membrane protein. Golgi apparatus Cell membrane Multi-pass membrane protein Note=Colocalizes with GOPC at the Golgi apparatus.
Domain	PF01534 Frizzled/Smoothened family membrane region PF01392 Fz domain
Function	Receptor for Wnt proteins. Component of the Wnt-Fzd-LRP5-LRP6 complex that triggers beta-catenin signaling through inducing aggregation of receptor-ligand complexes into ribosome-sized signalosomes. The beta-catenin canonical signaling pathway leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not yet clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to involve interactions with G-proteins. May be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues. Coreceptor along with RYK of Wnt proteins, such as WNT1.

> Gene Ontology [ TOP ]
Biological Process	GO:0001525 angiogenesis GO:0002521 leukocyte differentiation GO:0007159 leukocyte cell-cell adhesion GO:0007254 JNK cascade GO:0016055 Wnt signaling pathway GO:0030098 lymphocyte differentiation GO:0030217 T cell differentiation GO:0031098 stress-activated protein kinase signaling cascade GO:0032872 regulation of stress-activated MAPK cascade GO:0032874 positive regulation of stress-activated MAPK cascade GO:0033077 T cell differentiation in thymus GO:0033674 positive regulation of kinase activity GO:0035567 non-canonical Wnt signaling pathway GO:0042110 T cell activation GO:0043405 regulation of MAP kinase activity GO:0043406 positive regulation of MAP kinase activity GO:0043410 positive regulation of MAPK cascade GO:0043506 regulation of JUN kinase activity GO:0043507 positive regulation of JUN kinase activity GO:0045860 positive regulation of protein kinase activity GO:0046328 regulation of JNK cascade GO:0046330 positive regulation of JNK cascade GO:0048514 blood vessel morphogenesis GO:0051403 stress-activated MAPK cascade GO:0060070 canonical Wnt signaling pathway GO:0070302 regulation of stress-activated protein kinase signaling cascade GO:0070304 positive regulation of stress-activated protein kinase signaling cascade GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0071593 lymphocyte aggregation GO:0071594 thymocyte aggregation GO:0071900 regulation of protein serine/threonine kinase activity GO:0071902 positive regulation of protein serine/threonine kinase activity GO:0198738 cell-cell signaling by wnt
Molecular Function	GO:0017147 Wnt-protein binding GO:0030165 PDZ domain binding GO:0031625 ubiquitin protein ligase binding GO:0042813 Wnt-activated receptor activity GO:0044389 ubiquitin-like protein ligase binding
Cellular Component	GO:1990851 Wnt-Frizzled-LRP5/6 complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04150 mTOR signaling pathway hsa04310 Wnt signaling pathway hsa04390 Hippo signaling pathway hsa04550 Signaling pathways regulating pluripotency of stem cells hsa04916 Melanogenesis
Reactome	R-HSA-4608870: Asymmetric localization of PCP proteins R-HSA-3858494: Beta-catenin independent WNT signaling R-HSA-373080: Class B/2 (Secretin family receptors) R-HSA-1643685: Disease R-HSA-5663202: Diseases of signal transduction R-HSA-500792: GPCR ligand binding R-HSA-4086400: PCP/CE pathway R-HSA-5340588: RNF mutants show enhanced WNT signaling and proliferation R-HSA-4641263: Regulation of FZD by ubiquitination R-HSA-162582: Signal Transduction R-HSA-372790: Signaling by GPCR R-HSA-4791275: Signaling by WNT in cancer R-HSA-195721: Signaling by Wnt R-HSA-201681: TCF dependent signaling in response to WNT

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04150 mTOR signaling pathway
hsa04310 Wnt signaling pathway
hsa04390 Hippo signaling pathway
hsa04550 Signaling pathways regulating pluripotency of stem cells
hsa04916 Melanogenesis

Reactome

R-HSA-4608870: Asymmetric localization of PCP proteins
R-HSA-3858494: Beta-catenin independent WNT signaling
R-HSA-373080: Class B/2 (Secretin family receptors)
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-500792: GPCR ligand binding
R-HSA-4086400: PCP/CE pathway
R-HSA-5340588: RNF mutants show enhanced WNT signaling and proliferation
R-HSA-4641263: Regulation of FZD by ubiquitination
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-4791275: Signaling by WNT in cancer
R-HSA-195721: Signaling by Wnt
R-HSA-201681: TCF dependent signaling in response to WNT

Summary
Symbol	FZD8
Name	frizzled class receptor 8
Aliases	frizzled (Drosophila) homolog 8; frizzled homolog 8 (Drosophila); frizzled 8, seven transmembrane spanning r ......
Chromosomal Location	10p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between FZD8 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	FZD8
Name	frizzled class receptor 8
Aliases	frizzled (Drosophila) homolog 8; frizzled homolog 8 (Drosophila); frizzled 8, seven transmembrane spanning r ......
Chromosomal Location	10p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of FZD8 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	FZD8
Name	frizzled class receptor 8
Aliases	frizzled (Drosophila) homolog 8; frizzled homolog 8 (Drosophila); frizzled 8, seven transmembrane spanning r ......
Chromosomal Location	10p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of FZD8 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-1.338	0.00618
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.756	0.077
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-1.04	0.235
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.955	0.152
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.766	0.525
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	1.207	0.459
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.521	0.326
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.94	0.321
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.083	0.935
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.808	0.458
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-1.182	0.426
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.229	0.19

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of FZD8 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	FZD8
Name	frizzled class receptor 8
Aliases	frizzled (Drosophila) homolog 8; frizzled homolog 8 (Drosophila); frizzled 8, seven transmembrane spanning r ......
Chromosomal Location	10p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FZD8. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	FZD8
Name	frizzled class receptor 8
Aliases	frizzled (Drosophila) homolog 8; frizzled homolog 8 (Drosophila); frizzled 8, seven transmembrane spanning r ......
Chromosomal Location	10p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FZD8. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FZD8. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	FZD8
Name	frizzled class receptor 8
Aliases	frizzled (Drosophila) homolog 8; frizzled homolog 8 (Drosophila); frizzled 8, seven transmembrane spanning r ......
Chromosomal Location	10p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FZD8. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	FZD8
Name	frizzled class receptor 8
Aliases	frizzled (Drosophila) homolog 8; frizzled homolog 8 (Drosophila); frizzled 8, seven transmembrane spanning r ......
Chromosomal Location	10p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of FZD8 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	FZD8
Name	frizzled class receptor 8
Aliases	frizzled (Drosophila) homolog 8; frizzled homolog 8 (Drosophila); frizzled 8, seven transmembrane spanning r ......
Chromosomal Location	10p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between FZD8 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	FZD8
Name	frizzled class receptor 8
Aliases	frizzled (Drosophila) homolog 8; frizzled homolog 8 (Drosophila); frizzled 8, seven transmembrane spanning r ......
Chromosomal Location	10p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting FZD8 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse FZD8